View all active clinical trials around the US.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEA Phase 2 Single-Arm Study of Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early R...
TALQUETAMAB IN ELDERLY PATIENTSAn Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligib...
DARATUMUMAB COMBINATION INDUCTIONPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPhase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
IBERDOMIDE COMBINATION THERAPYThe Effect of Novel Treatments in Improving Renal Outcomes Among Patients With Light Chain Cast Nephropathy
LIGHT CHAIN CAST NEPHROPATHY IN MYELOMA PATIENTSPilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD...
DARATUMUMAB FOR PATIENTS WITH RENAL FAILUREBiomarkers of AKI in Patients with Multiple Myeloma Receiving Daratumumab: a Pilot Study
ACUTE KIDNEY INJURY IN MYELOMA PATIENTSThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEAn Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligib...
DARATUMUMAB COMBINATION INDUCTIONPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEThe Effect of Novel Treatments in Improving Renal Outcomes Among Patients With Light Chain Cast Nephropathy
LIGHT CHAIN CAST NEPHROPATHY IN MYELOMA PATIENTSBiomarkers of AKI in Patients with Multiple Myeloma Receiving Daratumumab: a Pilot Study
ACUTE KIDNEY INJURY IN MYELOMA PATIENTSThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Phase 2 Single-Arm Study of Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early R...
TALQUETAMAB IN ELDERLY PATIENTSPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEThe Effect of Novel Treatments in Improving Renal Outcomes Among Patients With Light Chain Cast Nephropathy
LIGHT CHAIN CAST NEPHROPATHY IN MYELOMA PATIENTSThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Phase 2 Single-Arm Study of Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early R...
TALQUETAMAB IN ELDERLY PATIENTSPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPhase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
IBERDOMIDE COMBINATION THERAPYThe Effect of Novel Treatments in Improving Renal Outcomes Among Patients With Light Chain Cast Nephropathy
LIGHT CHAIN CAST NEPHROPATHY IN MYELOMA PATIENTSThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).